GlaxoSmithKline's Shingrix Approved in the U.S. for Prevention of Shingles in Adults Aged 50 and … Post author:Sam Post published:October 22, 2017 Post category:BioPharma Shingrix is a non-live, recombinant subunit vaccine given intramuscularly in two doses. Source: BioSpace You Might Also Like 3 Biotechs Facing Big FDA Decisions in October September 26, 2017 Sources Reveal Tesaro is Unlikely to Find a Buyer July 13, 2017 Creative BioMart Launched A Series Of Activities And Promotions Recently March 19, 2017
